2seventy bio, Inc. is a biotechnology company focused on developing innovative cell therapies for cancer treatment
The company harnesses the power of genetics and advanced cellular engineering to create novel therapeutics aimed at addressing unmet medical needs in oncology. By leveraging its proprietary platforms, 2seventy bio works on developing personalized treatment options that target specific tumors and aims to improve patient outcomes through precision medicine. The company's commitment to research and development drives its efforts to bring transformative therapies to market for patients battling various forms of cancer.
2seventy Bio finalized an asset purchase agreement with Novo Nordisk involving the Hemophilia A program and in vivo gene editing technology. The 2seventy bio team will join Novo Nordisk, focusing on advancing the technology.
FDA approves Bristol-Myers Squibb and 2seventy Bio Abecma (ide-cel) for relapsed or refractory multiple myeloma after ≥2 prior therapies. Extends progression-free survival by 13.3 months vs. standard care.
FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson & Johnson's Carvykti in second-line multiple myeloma.
Novo Nordisk's Alhemo (concizumab) receives a positive opinion from the EMA's CHMP for hemophilia A or B with inhibitors. The once-daily subcutaneous treatment showed significant bleeding reduction in clinical trials. European Commission decision expected in two months.
2seventy bio halts enrollment in its KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company expects strong growth following FDA approval in April.
Shares of Science Applications International Corporation (NYSESAIC) fell sharply during Monday’s session after the company reported financial fourth-quarter EPS below estimates.
Shares of Nuvei Corp (NASDAQNVEI) rose sharply in today’s pre-market trading following a report indicating the company is in buyout talks with Advent International. Nuvei shares jumped 14.1% to $24.82 in pre-market trading
Shares of Cardlytics, Inc. (NASDAQCDLX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter earnings.
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales.
Shares of Advanced Micro Devices, Inc. (NASDAQAMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD reported fourth-quarter non-GAAP earnings per share of 77 cents per share on revenue of $6.17 billion. AMD shares dipped 3.8% to $165.49 on Wednesday.
U.S. stocks traded mostly lower midway through trading, with the Nasdaq Composite falling more than 200 points on Wednesday. The Dow traded up 0.08% to 38,497.13 while the NASDAQ fell 1.41% to 15,291.02. The S&P 500 also fell, dropping, 0.81% to 4,885.29.
